symptoms, with no reactions nor disabilities, still on
PB form. (Barreto et al,2017) Multibacillary leprosy
presents as more than five skin lesions with
hypoesthesia or anesthesia, symmetrical nerve
thickening, and nerve function deficits, madarosis,
leonine facies, and deformities in an advanced
stage.(Bryceson et al,1990). The patient was
diagnosed as multibacillary leprosy due to having
madarosis and slit skin smear revealed acid-fast
bacilli with Bacteriological Index 4+. The
differential diagnosis of tinea manus can be ruled
out because the lesions in tinea are usually well-
defined with elevated or more active edges even
though they are accompanied by dry skin and affect
only one part of the body. However, KOH
verification was negative. Postinflammatory
hyperpigmentation can be excluded because there is
no history of injury or infection that occurred in the
patient's left hand before.
The patient then prescribed with multi-drug
therapy for children with MB leprosy and advice on
daily care routinely. In Indonesia, MDT for Children
is divided into under five years, 5-9 years, 10-15
years, and more than 15 years. In patients treated
with MDT MB children, which consists of
rifampicin 450 mg every month, clofazimine 150 mg
at the beginning of the month and 50 mg per day,
and dapsone 50 mg per day. The prognosis of the
patient is good due to no disabilities and deformities
were seen.
4 CONCLUSION
Early diagnosis and treatment is a fundamental
strategy to prevent leprosy transmission. Leprosy in
children below 15 years old is a robust indicator of
the active source of infection in the community
where they live. Subclinical infection among
children is considered a sentinel for hidden
prevalence in the general population, as well. Early
diagnosis in children can be hard, even for those
with experience in dealing with this disease, because
of the full range of clinical aspects of the skin
lesions and mainly due to the difficulty of
performing the clinical peripheral nerve evaluation.
The younger the child, the more difficult the changes
in sensitivity are to evaluate. Ongoing research is
trying to develop better diagnostic tests and to
advance chemoprophylaxis and immunoprophylaxis
approaches. However, for now, we must maintain
leprosy expertise and improve the health
professionals training for leprosy diagnosis
REFERENCES
Abeje T, Negera E, Kebede E, Hailu T, Hassen I, Lema T,
et al. 2016. Performance of general health workers in
leprosy control activities at public health facilities in
Amhara and Oromia states. Ethiopia BMC Health Serv
Res. 16:122.
Barreto JG, Andrey M, Frade C, Filho FB. 2017. Leprosy
in Children. Pediatr Infect Dis. (June):23-28.
doi:10.1007/s11908-017-0577-6
Bryceson A, Pfaltzgraff RE. 1990. Leprosy, 3
rd
ed. New
York: Churchill Livingstone.
Jain S, Reddy RG, Osmani SN, et al. 2002. Childhood
leprosy in an urban clinic, Hyderabad, India: clinical
presentation and the role of household contacts. Lepr
Rev.73:248-53.
Kaur I, Kaur S, Sharma VK, Kumar B. 1991. Childhood
leprosy in northern India. Pediatr Dermatol. 8:21-4
Singal A, Chhabra N, 2010. Childhood Leprosy. In: Kar
HK, Kumar B, editor. IAL Textbook of Leprosy. New
Delhi: Jaypee Brothers Medical Publishers (P) Ltd.. P.
360-369.
.Kementerian Kesehatan RI, Direktorat Jenderal
Pengendalian Penyakit dan Penyehatan Lingkungan.
2014. Pedoman Program Pengendalian Penyakit
Kusta. Jakarta: Direktorat Jenderal Pengendalian
Penyakit dan Penyehatan Lingkungan.
Lee D.J., Rea T.H., Modlin R.L. Leprosy. 2012. In:
Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller A.S.,
Leffell D.J., Wolff K. (Eds.): Fitzpatrick’s
Dermatology In General Medicine. 8
th
edition. New
York: McGraw-Hill Companies. p.2253-63.
Richardus JH, Oskam L. 2019. Protecting people against
leprosy : Chemoprophylaxis and immunoprophylaxis.
Clin Dermatol. 33(1):19-25.
doi:10.1016/j.clindermatol.2014.07.009
Romero-Montoya IM, Beltrán-Alzate JC, Ortiz-Marín DC,
DiazDiaz A, Cardona-Castro N. 2014. Leprosy in
Colombian children and adolescents. Pediatr Infect Dis
J. 33:321–2.
Shetty VP, Ghate SD, Wakade AV et al. 2013. Clinical,
bacteriological, and histopathological characteristics
of newly detected children with leprosy: a population-
based study in a defined rural and urban area of
Maharashtra, Western India. Indian J Dermatol
Venereol Leprol.79:512-7.
WHO. Global Leprosy Strategy 2016–2020: Accelerating
towards a leprosy-free world. New Delhi (India):
World Health Organization, Regional Office for South-
East Asia; 2016. This document gives a special focus
on early case detection on children before visible
disabilities occur. One of the main targets is zero
disabilities among new pediatric patients by 2020.
World Health Organization. 2016. Global Leprosy Update,
2015: Time for Action, Accountability, and Inclusion.
Geneva: Weekly Epidemiological Record. 19: 405-420.
Wisnu IM, Sjamsoe-Daili E, dan Menaldi SL. 2016.
Kusta.. In: Menaldi SLSW, Bramono K, dan Indriatmi
W. (eds.) Ilmu Penyakit Kulit dan Kelamin. Edisi 7.
Jakarta: Badan Penerbit FK UI. p. 87-102.